Tern plc Investor Webinar Recording in Full (VIDEO)

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that a recording of the investor webinar held on Tuesday 21 November 2023 and featuring presentations by Tern’s portfolio companies Device Authority, Wyld Networks and Talking Medicines, together with a question and answer session, is available to view below:

Video presentation of Tern PLC Capital Markets Day held on 21 November 2023. Presenters include Ian Ritchie and Al Sisto from Tern PLC together with Darron Antill from Device Authority, Jo Halliday from Talking Medicines and Alastair Williamson from Wyld Networks.

Tern Plc is using its experience in pioneering leading-edge tech combined with a deep reach into expanding world markets to unlock the potential of UK companies who may be starting local, but are dreaming global. If you are a company seeking to disrupt existing markets, or even creating a whole new sector, tern is the long term partner who can help you change your business, and then the world, for the better.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search